No Data
Goldman Sachs released a deep investment value report on China's Biomedical sector, highlighting a bullish outlook on ZAI LAB (ZLAB.US/9688.HK) and four other companies.
Recently, Goldman Sachs released an in-depth investment value analysis report on China's biotechnology. Goldman Sachs believes that it remains Bullish on the biotechnology sector within China's Medical and Healthcare market, as China's innovation is gaining and will continue to gain Global recognition. A number of leading biotechnology companies are expected to achieve breakeven in 2025/2026. This profitability inflection point is of milestone significance for China's biotechnology industry. Goldman Sachs also stated that ZAI LAB (ZLAB.US/9688.HK), Legend Biotech, INNOCARE, BEIGENE, and INNOVENT BIO are preferred symbols, as these companies have all experienced core catalytic events this year.
Why Legend Biotech Corporation (LEGN) Is Among the Best Healthcare Stocks To Buy According to Analysts
SA Asks: Which Big Pharmas Would Be Most Impacted by Higher Tariffs?
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
Where Legend Biotech Stands With Analysts
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
廣理右汛 : Support. Sending you a block.
adaptable Otter_3218 : Ag